Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Do you think they will try it again considering they got smacked last time:
A. Respondent UBS O’Connor cease and desist from committing or causing any
violations and any future violations of Rule 105 of Regulation M of the Exchange
Act.
B. Respondent UBS O’Connor is censured.
C. Respondent shall, within 20 days of the entry of this Order, pay disgorgement of
$3,787,590, prejudgment interest of $369,766, and a civil penalty of $1,140,000 to
the United States Treasury. If any payment is not made by the date the
payment is required by this Order, the entire outstanding balance of disgorgement,
prejudgment interest, and civil penalties, plus any additional interest accrued
pursuant to SEC Rule of Practice 600 or pursuant to 31 U.S.C. 3717, shall be due
and payable immediately, without further application. Payment must be made
in one of the following ways:
I am out at .43 after reading this little nugget:
To Our Stockholders,
You are cordially invited to attend a Special Meeting of Stockholders of BioPharmX Corporation. The meeting will be held at the law offices of Fenwick & West LLP, counsel to BioPharmX Corporation, located at 801 California Street, Mountain View, California 94041, on Tuesday, March 28, 2017 at 10:00 a.m. (Pacific Time) for the following purposes:
1.
To approve an amendment to our certificate of incorporation to increase the total number of authorized shares of common stock from 90,000,000 shares to 450,000,000 shares (the " Authorized Share Increase Proposal ").
2.
To approve an amendment to our certificate of incorporation to effect a reverse stock split at a ratio not less than 1-for-2 and not greater than 1-for-25, with the exact ratio to be set within that range at the discretion of our board of directors before January 31, 2018 without further approval or authorization of our stockholders (the " Reverse Split Proposal "). The board of directors may alternatively elect to abandon such proposed amendment and not effect the reverse stock split authorized by stockholders, in its sole discretion.
3.
Contingent upon (i) the approval of the Authorized Share Increase Proposal or (ii) the Reverse Split Proposal and the Board's subsequent determination to effect the reverse split, to approve the amendment of our 2016 Equity Incentive Plan such that the number of shares available for issuance thereunder will increase by 20,000,000 shares on a pre-split basis (the " Plan Increase Proposal ").
In addition, stockholders may be asked to consider and vote upon such other business as may properly come before the meeting or any adjournment or postponement thereof.
On or about [ · ], 2017, the proxy materials related to this special meeting will be mailed to our stockholders.
The board of directors unanimously believes that (i) the Authorized Share Increase Proposal, (ii) the Reverse Split Proposal and (iii) the Plan Increase Proposal are in our best interests and that of our stockholders. Accordingly, our board of directors recommends a vote (i) FOR the Authorized Share Increase Proposal, (ii) FOR the Reverse Split Proposal and (iii) FOR the Plan Increase Proposal.
Please use this opportunity to take part in our company's affairs by voting on the business to come before the meeting. It is important that your shares be represented and voted whether or not you plan to attend the special meeting in person. You may vote by attending the special meeting and voting in person. You also may vote by submitting a proxy. Voting by proxy will ensure your shares are represented at the special meeting. Please review the voting instructions in the enclosed proxy card or the information forwarded by your bank, broker or other holder of record.
I'm thinking just south of $1.10 on an EOD run.
Can this possibly hit a $1.00 today
2017 Outlook:
2017 Outlook and Projected Future Milestones
Full results for the phase II efficacy and safety study of alidornase alfa expected to be announced during the first quarter of 2017.
Full results for the phase II efficacy and safety study of OPRX-106 expected to be announced during the second half of 2017.
Completion of enrollment in the phase III trial of pegunigalsidase alfa for the treatment of Fabry disease expected in 2017; interim data analysis anticipated in 2018 to support EMA and other regulatory filings outside of the United States.
If superiority to Fabrazyme is not yet achieved at that time, as shown in the interim data, the trial will continue for an additional year before reporting two-year data to support a U.S. regulatory filing.
If superiority to Fabrazyme is not yet achieved at that time, as shown in the interim data, the trial will continue for an additional year before reporting two-year data to support a U.S. regulatory filing.
Present, via two key opinion leader (KOL) presentations and a poster, pegunigalsidase alfa clinical data at the 13th Annual WORLD Symposium™ to be held in February 2017.
Present at the 5th Update on Fabry Nephropathy: Biomarkers, Progression and Treatment Opportunities in April 2017.
Present, at the 40th European Cystic Fibrosis Conference, full data from the Company’s phase II efficacy and safety study of alidornase alfa, in June 2017, and at the North American Cystic Fibrosis Conference in November 2017.
Potential partnership for alidornase alfa.
Potential collaboration for alidornase alfa with the Cystic Fibrosis Foundation.
Potential partnership for oral anti-TNF.
2016 Recap:
2016 and Recent Clinical Highlights
Received purchase order from the Brazilian Ministry of Health for purchase of alfataliglicerase to treat Gaucher patients in Brazil. The order consists of a number of shipments during 2017, in increasing volumes, for a total of approximately $24.3 million. The size of the final shipment of the order represents annual revenues of approximately $42.0 million. The Brazilian Ministry of Health’s order was published in the December publication of Brazil’s Official Diary of the Union (Diário Oficial).
Reported positive interim results from the Company’s phase II clinical trial of alidornase alfa (PRX-110) for the treatment of Cystic Fibrosis, which results include a clinically meaningful increase in percent predicted forced expiratory volume in one second (ppFEV1).
Initiated patient enrollment in the Company’s phase II clinical trial of OPRX-106 for the treatment of ulcerative colitis. The Company is developing OPRX-106 to be the first ever oral protein treatment, as currently there are no other oral protein treatments available.
Received regulatory approval of alfataliglicerase in Brazil for children four years old and above with a confirmed diagnosis of Type I Gaucher disease.
Worked closely with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) to determine the phase III clinical trial program for pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease:
Initiated and enrolled patients in a global phase III trial of pegunigalsidase alfa versus Fabrazyme® to support a BLA filing in the United States, with a 12-month non-inferiority interim analysis to support an MAA filing with the EMA.
Determined a 12-month switch-over study from Replagal® will also be conducted to support FDA and EMA filings.
Initiated and enrolled patients in a global phase III trial of pegunigalsidase alfa versus Fabrazyme® to support a BLA filing in the United States, with a 12-month non-inferiority interim analysis to support an MAA filing with the EMA.
Determined a 12-month switch-over study from Replagal® will also be conducted to support FDA and EMA filings.
Presented positive 6- and 12-month interim clinical data on pegunigalsidase alfa at the 12th Annual WORLD Symposium™ in March 2016.
Exchanged $54.1 million principal amount of the Company’s $69.0 million 4.50% Senior Convertible Notes due 2018 for $40.2 million principal amount of newly issued 7.50% Senior Secured Convertible Notes due 2021 and approximately 23.8 million shares of common stock. Concurrently, the Company sold, in a private placement, $22.5 million principal amount of 2021 Notes.
The Company had a strong cash balance of approximately $63.0 million as of December 31, 2016, which is currently projected to fund operations into late 2019.
Looks like someone had a market order in and the MM's pounced on it.
Still on a 3 month up swing except for a spike or two.
This still has a ton of upside IMO.
IMO The MM's are still playing with this one trying to pick up cheap shares before Data comes out in March.
Tight trading range today
Prime for a Break out
Who is Clay Trader ???
I am just doing some DD and was passing it along. From now on I will keep my DD unto me.
Golden Cross coming :}
Finally the next leg up.
Let her rip tater chip.
When are the MM going to let this puppy run. Still way under valved.
When are the MM going to let this puppy run. Still way under valved.
I don't want to be the Debbie downer but what is keeping Serge from flying under the Nova flag and never relisting Savi
It seems that Savi has already partnered with Nova and is working on the Corona Discharge CO2 Gas Dissocaition Module
and they are advertising the Dyno plug there Why relist ?
Why???
Because they have been so truthful to this point.
The only thing I will believe at this point is.
If it starts trading again its trading again.
If it never trades again than it won't trade again.
But it sucks to get PR's and summary's from the company that turn out to be lies.
I found it on the Savi corp. website under investor relations updates.
This is not much but at least it looks like they are trying.
Sorry if this has already been posted
This is the latest 8K quarterly filing for SaviCorp which will be posted to the SEC EDGAR site once we complete the SEC From 10 to become re-listed. SaviCorp council is currently working to re-list SVMI at which time this 8K will be filed as per regulations with SEC.
Section 8 - Other Events
8.01 Other Events (Company Business, EDGAR Reporting, SEC and Secondary Stock Sales Update)
1. We have caught up on our Public Reporting on EDGAR.
On June 19, 2015, SaviCorp (“Company”) filed our Form 10-K for the fiscal year ending December 31, 2014 on EDGAR. On June 22, 2015, we filed our Form 10-Q for the fiscal quarter ending March 31, 2015. On June 29, 2015, we filed our 10-Q for the fiscal quarter ending September 30, 2014. Upon that filing, we were completely caught up on our public reporting responsibility. Our Form 10-Q for the fiscal quarter ending June 30, 2015 is due by August 15, 2015.
2. SEC De-Registration of SaviCorp.
We received a letter from the SEC dated July 13, 2015 containing an Order stating that the SEC has accepted an Offer of Settlement from the Company and pursuant to Section 12(j) of the Exchange Act (of 1934, as amended), the registration of the Company’s securities (common stock) registered pursuant to Exchange Act Section 12 is revoked.
3. Trading of SaviCorp’s Common Stock.
Our common stock is not trading on otcmarkets.com. We have commenced work on a Form 10 registration statement and plan to file it with the SEC to re-register our common shares. We also plan to retain a broker-dealer to file a Form 211 with FINRA and plan to have our common shares trading in the “secondary” public market once again. We do not know the timing of these efforts and are not able to guarantee the results.
4. Our Business Report for the first half of 2015.
We are licensing “DynoFlo HHO” for distribution; a new invention/patent of our Chairman/CEO, Serge Monros. This “after market” product can produce “on demand” hydrogen; primarily for use with large diesel engines. This technology reduces the need for potentially dangerous hydrogen storage systems and lowers the cost of utilization of the perceived benefits of hydrogen in reducing soot particles and increasing diesel engine efficiency. We plan to test and offer this unit for mobile and stationary industrial, commercial and maritime engines. The first pre-production unit is scheduled for installation on a freightliner 12.7 Detroit diesel engine to determine its potential benefits. Operating funds allowing, we plan to initiate nationwide marketing of DynoFlo HHO and see it as a diesel engine market complement to our DynoValve gasoline engine marketing efforts.
We are expanding our Asian marketing efforts. We are dealing with a South Korean company that took delivery of an order of 200 DynoValves in May of this year. They are in the midst of training with a SaviCorp technician for proper installations in anticipation of future orders. We have a small “satellite” presence in Seoul, Korea, with this company and anticipate establishing a licensing agreement with them; however, we are not to that stage as yet and cannot guarantee such a development. We also met with the same company representatives in our US offices in July of this year and are discussing the testing of 10 DynoFlo HHO units in Korea as well.
In Mid-May of 2015, our Vice President of Operations, Vince Manship, and Chief Technician, Mike Rockwood completed a trip to Beijing, People’s Republic of China. We have a Master Distribution Agreement in place with Beijing FlyingGlob Environmental Technology Limited Company for the distribution of DynoValves largely in the Peoples’ Republic of China (“MDA”). The primary purpose of this trip was to conduct DynoValve testing at the “Beijing Proving Grounds,” the Chinese government’s vehicle emissions testing facility; which provided results as required under our MDA. We are also cultivating other contacts made with Chinese governmental officials who we believe are aware of the potential benefits of Dynovalve when installed in vehicles; potentially assisting the Chinese with their well-known air pollution problems. The Chinese government is conducting more testing of DynoValve which we believe will result in the issuance of a classification known as “Green Product,” which is thought to give the product more marketing potential in China. We don’t know the timing of this testing and whether DynoValve will be able to achieve this status.
Operational funds permitting, we are planning to send Mr. Manship to Bangkok, Thailand later this year to witness emissions testing of the DynoValve to be conducted by the Thai government. We will be seeking “Green” status in Thailand as well and are contacting Thai companies seeking licensing partners there. We also have plans for Mr. Manship to travel to Dubai while in route to Thailand. Mr. Manship plans to meet with UAE government officials to discuss the “Green City Project” in Abu Dhabi.” We have a master distribution agreement, titled “International Exclusive Distribution Agreement” (“MDA”), in place with a company known as DynoGreen Tech, LLC (a CA LLC). This licensing agreement includes territory in Dubai and the UAE. Also known as “Savvy Green,” Green status is being sought by Savvy Green in India, as the company works with Tata Motors of India.
Domestically, we have an ongoing relationship with Walker Products, in Garden Grove, California, one of the largest “after market” auto parts retail firms in the United States. We have a product known as the “DynoPlug Spark Plug” for which Walker Products will begin prototype production. AutoPlug Spark Plug is another SaviCorp product that we believe will help reduce emissions for automobiles. We also have an agreement with Walker Products just going into place allowing them to market DynoValve under their private label as “EconoValve.” Walker Products is currently arranging for testing of the EconoValve unit.
During the 2nd quarter of 2015, SaviCorp was awarded a US Government System for Award Management (SAM) number. With this designation, we will appear on the US Government’s approved list of vendors and we’ll be able to bid on contracts to supply our products for installation and use on government vehicles in all our various United States departments, such as the military, postal service, National Park Service, etc.
We are continuing to work with the US-approved Olson-EcoLogic Engine Testing Laboratories, located in Fullerton, California, to gain certification for fuel economy and emission reduction for DynoValve. We use a variety of different vehicles to have more test results available.
We currently have an inventory of 3500 DynoValves ready for shipment. Our licensor also has parts available to assemble another 4000 DynoValves so that additional DynoValves could be made available for distribution. We are continuing to research product marketing firms that may be able to assist us in the marketing of our products.
All depends on what kind of dust.
Dust from a cattle drive or
Dust from an atomic bomb. LOL
I think Serge should at least give all of us shareholders a couple free dyno valves for our troubles.
I believe that DFW has a NDA.
Solly8 You said savi would not attend the hearing because of funds.
But they said:
DFW they say the truth can set you free.
Free to do what I have no idea.
Thanks for the response you always have been a straight shooter.
We need something from the company now.
Something we can get revved up about.
What's their path forward.
Remember when Serge gave the state of the union or Q&A's whatever you want to call then. ( I think ICE set them up )
Now would be a good time for one of those.
Serge just can't leave us hanging for months.
Right now it's time for the truth the whole truth and nothing but the truth. No we might's or we may's, if', but's or maybe's.
It's been a long week of negative information.
Let's think about the positives.
1. The sun will come up tomorrow (unless it is raining but the sun is still above the clouds).
2. You will wake up tomorrow (The good Lord willing).
3. The last Q is in so savi is now current with their filings.
4. Rumor has it that savi has a market maker to sponsor them.
5. The suspension will be lifted tomorrow night at midnight.
6.And Sir bash-a-lot gave us a song.
What more could we ask for?
Feel free to add to the list.
According to solly8 savi has a strategy.
If savi has the last Q done and approved, they have a MM lined up to sponsor them, and lawyers going to speak on their behalf at least that sounds like a strategy to me.
We just have to hope that plan is enough to start savi on the road off the gray sheet.
I know I saw that the yesterday. I was just trying to find that ray of light. I know its apples to oranges but just through it out there
JIM I agree with freedoms petition too as I stated, But I don't think the SEC is protecting us. we are in the savi bubble.
I think that the SEC is protecting the average investor from savi step out of the bubble and try to look at savi from an outsider.
At this moment in time I would have to agree with cool's post 34450. As harsh as it may sound savi isn't real appealing right now.
This was an IPO not a suspension but the fact remains it was trading on the GRAYS.
Not bad it can't hurt.
There was this from the 8K that came out.
TSH when I researched the GREY SHEETS yesterday that was the conclusion I came to also.
I was going to post similar info,
but lately I have been bashed and called names for posting anything negative about savi so I didn't share.
Good luck to all I hope savi is the exception to the rule.
Never mind I found the answer I was looking for
Thanks MLM is there a standard time that they will be on the gray sheet listing. 30 60 90 days
DFW maybe you can help me out here.
When savi is current and the suspension is lifted the bones will be gone.
and the yield should be gone is there any other signs that will be attached to savi.
If so what will it take to be lifted?
Thanks in advanced BB
the quarterly period ended June 30, 2014 Just showed up at 1:05est
Ahh the 25"th only 5 days left in the penatly box.
Another 10q in.
And only 6 shopping months left until Christmas.
Are you kidding me.
Are you actually reading the filings or just seeing Q's & K's I admit its a step in the right direction, but if you are seeing light at the end of the tunnel than you my friend are delusional.
Going Concern Considerations
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. In 2014 and 2015, the Company had limited operations and resources. At March 31, 2015, the Company is in a negative working capital position of $16,588,779 and has a stockholders' deficit of $16,570,262. Additionally, as of March 31, 2015 the Company faced substantial challenges to future success as follows:
That's 16.5 million in debt. And filings are not going to make that go away. only revenue will and that was my point.
Maybe you should go back to watching and those of us that do real DD keep it real here.
Getting current is absolutely a HUGE step.
But reading the Q's this company is still in big trouble if they
don't land one of the big contracts they have led us to believe
they have.
Savi also need to address the share issue. It is getting out of
hand 8 billion really.